泰凌医药2020年报

Annual Report2020年報(Incorporated in the Cayman Islands with limited liability)(於開曼群島註冊成立之有限公司) CONTENTS 目錄2Financial Highlights財務摘要3Chairman’s Statement主席報告6Management Discussion and Analysis管理層討論及分析23Directors and Senior Management董事及高級管理層29Corporate Governance Report企業管治報告55Environmental, Social and Governance Report環境、社會及管治報告101Report of the Directors董事會報告117Board of Directors and Board Committees董事會及董事委員會118Corporate Information公司資料120Independent Auditor’s Report獨立核數師報告133Consolidated Statement of Profit or Loss綜合損益表135Consolidated Statement of Profit or Loss and Other Comprehensive Income綜合損益及其他全面收益表136Consolidated Statement of Financial Position綜合財務狀況表138Consolidated Statement of Changes in Equity綜合權益變動表139Consolidated Statement of Cash Flows綜合現金流量表142Notes to the Consolidated Financial Statements綜合財務報表附註 Financial Highlights財務摘要 China NT Pharma Group Company Limited I Annual Report 20202FIVE-YEAR FINANCIAL SUMMARYResultsFor the year ended 31 December截至12月31日止年度20202019201820172016RMB’000RMB’000RMB’000RMB’000RMB’000人民幣千元人民幣千元人民幣千元人民幣千元人民幣千元(restated)(restated)（重列）（重列） Turnover營業額221,731153,468571,521604,846359,609Gross profit毛利134,90490,257422,002484,235253,833(Loss)/profit from operations經 營（ 虧 損 ）╱ 溢 利(113,752)(250,766)(480,944)269,57864,575(Loss)/profit before taxation除 稅 前（ 虧 損 ）╱ 溢 利(200,289)(355,141)(561,999)226,42835,543(Loss)/profit for the year from discontinued operations年內來自已終止經營業務 的（ 虧 損 ）╱ 溢 利(168,644)(237,796)(361,903)(48,916)91,060(Loss)/profit for the year年 內（ 虧 損 ）╱ 溢 利(359,913)(593,202)(963,762)161,629115,760 Assets and LiabilitiesAt 31 December於12月31日20202019201820172016RMB’000RMB’000RMB’000RMB’000RMB’000人民幣千元人民幣千元人民幣千元人民幣千元人民幣千元 Total non-current assets非流動資產總值718,1101,488,9301,637,0711,670,5761,578,145 Total current assets流動資產總值480,860309,344590,0911,089,143984,594Total current liabilities流動負債總額1,101,7701,625,5171,340,9851,207,0031,367,579 Net current liabilities流動負債淨額(579,477)(1,316,173)(750,894)(117,860)(382,985) Total assets less current liabilities總資產減流動負債138,633172,757886,1771,552,7161,195,160Total non-current liabilities非流動負債總額116,21170,834394,608123,963156,138 Net assets資產淨值22,422101,923491,5691,428,7531,039,022 Total equity attributable to equity shareholders of the Company本公司權益股東應佔權益總額16,279105,258489,2921,420,3801,027,083 五年財務概要業績資產及負債 Chairman’s Statement主席報告 中國泰凌醫藥集團 I 年度報告20203Dear Shareholders,On behalf of the board (the “Board”) of directors (the “Directors”) of China NT Pharma Group Company Limited (“NT Pharma”) together with its subsidiaries, the “Group”), I hereby present the annual report of the Company for the year ended 31 December 2020.NT Pharma is a technology-based pharmaceutical company integrated with research and development (“R&D”), manufacturing and sales of its own products. With its products covering therapeutic areas including central nervous system (“CNS”), oncology and hematology. NT Pharma owns two new National Class 1 drugs, one wellknown international innovative brand-name drug and a number of generic drugs. The Group conducts its drug manufacturing through three subsidiaries, namely Suzhou First Pharmaceutical Co., Ltd.* (“Suzhou First”), Jiangsu NT Biopharma Co., Ltd.* (“Jiangsu Biopharma”) and NT Pharma (Changsha) Co., Ltd.* (“Changsha Pharma”). The Group owns several sales and distribution companies with around 1,000 sales professionals and R&D specialists. It also has an extensive sales network in the People’s Republic of China (“China” or “PRC”), covering nearly 10,000 hospitals.In the year of 2020, the Group devoted much effort to the adjustment and restructuring of its sales model, tightening of cost control and improvement of its financial condition. The overall revenue of the Group from continuing operations for the year ended 31 December 2020 (the “Year under Review”) increased by RMB68.2 million to RMB221.7 million, as compared with RMB153.5 million for the corresponding period in 2019. Operating loss from continuing operations for the year ended 31 December 2020 decreased by RMB137 million to RMB113.8 million, as compared with an operating loss of RMB250.8 million for the corresponding period in 2019. The Group recorded a loss of RMB191.3 million for the year ended 31 December 2020, as compared with a loss of RMB355.1 million for the corresponding period in 2019, representing a decrease of 46.1% year on year.尊敬的各位股東：本人謹代表中國泰凌醫藥集團有限公司（「泰凌醫藥」，連同其附屬公司，合稱「本集團」）董 事（「 董 事 」）會（「 董 事 會 」）呈 列 本 公 司 截 至2020年12月31日止年度之年報。泰 凌 醫 藥 是 一 間 集 研 究 與 開 發（「 研 發 」）、 生產、銷售自有藥品為一體化的科技製藥公司。藥品覆蓋中樞神經系統（「中樞神經系統」）、腫瘤及血液等治療領域。泰凌醫藥擁有兩個國家一類新藥、一個國際知名原研品牌藥及多個自有仿製藥。本集團通過三間附屬公司蘇州第壹製藥有限公司（「蘇州第壹製藥 」）、 泰 凌 生 物 製 藥 江 蘇 有 限 公 司（「 江 蘇 生物 製 藥 」）及 泰 凌 醫 藥（ 長 沙 ）有 限 公